Choroidal Neovascularization: all 214 studies
Page 1 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular DegenerationNot yet recruitingNCT07798375Phase 2
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)RecruitingNCT07496567Phase 2/3
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)RecruitingNCT07440225Phase 2/3
- Deep Learning-Based OCTA Quantification and Modeling for Predicting Long-Term Anti-VEGF Efficacy in mCNVNot yet recruitingNCT07402629
- AVIGA3 (Cohort 2.0)RecruitingNCT07255859Not applicable
- Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular NeovascularizationNot yet recruitingNCT07187804Phase 4
- The Treatment Burden of Myopic Choroidal NeovascularizationNot yet recruitingNCT07009574
- Effect of Video Viewing on Intravitreal Injection ExperienceRecruitingNCT07002372Not applicable
- An Interpretable Fundus Diseases Report Generating System Based On Weakly LabelingsNot yet recruitingNCT06918028
- Faricimab Quarterly Maintenance for Neovascular Age Related Macular DegenerationRecruitingNCT06742307Phase 4
- Study on the Biomarkers of Anti-VEGF Treatment for Choroidal NeovascularizationNot yet recruitingNCT06243406
- Biomarkers and Choroidal NeovascularizationRecruitingNCT04439708
- Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT05269966Phase 4Results posted
- Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedNCT04774926Phase 4Results posted
- Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
- An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedNCT04597632Phase 3Results posted
- Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedNCT04264819Phase 3Results posted
- A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular DegenerationCompletedNCT04239027Phase 3Results posted
- Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
- A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMDCompletedNCT03953079Phase 2Results posted
- Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT03452527Phase 2Results posted
- Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular DegenerationCompletedNCT03038880Phase 2Results posted
- A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT02484690Phase 2Results posted
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2CompletedNCT02434328Phase 3Results posted
- Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT02358889Phase 2Results posted
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1CompletedNCT02307682Phase 3Results posted
- Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedNCT02214628Phase 2Results posted
- A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.CompletedNCT02034006Phase 3Results posted
- Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)CompletedNCT01972789Phase 4Results posted
- Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDCompletedNCT01948830Phase 3Results posted
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01944839Phase 3Results posted
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01940900Phase 3Results posted
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTerminatedNCT01940887Phase 3Results posted
- Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT01922102Phase 3Results posted
- An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.CompletedNCT01908816Phase 3Results posted
- ESBA1008 Microvolume StudyCompletedNCT01849692Phase 2Results posted
- Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.CompletedNCT01840410Phase 3Results posted
- Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular DegenerationCompletedNCT01835015Phase 1Results posted
- Indocyanine Angiographic Changes of Choroidal Neovascularization by RanibizumabCompletedNCT01810042Phase 4Results posted
- Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVOCompletedNCT01580020Phase 4Results posted
- Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal VasculopathyCompletedNCT01469156Phase 1/2Results posted
- Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMDCompletedNCT01414153Phase 2Results posted
- Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With RanibizumabTerminatedNCT01402544Phase 2/3Results posted
- VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)CompletedNCT01249664Phase 3Results posted
- Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT01217944Phase 3Results posted
- 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)CompletedNCT01175395Phase 1/2Results posted
- Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)CompletedNCT01148511Phase 4Results posted
- Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular DegenerationCompletedNCT01027468Not applicableResults posted
- Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMDTerminatedNCT01021956Phase 2Results posted
- The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular DegenerationTerminatedNCT00857259Phase 2Results posted
- Ranibizumab (Lucentis) for Polypoidal Choroidal VasculopathyCompletedNCT00837330Phase 1/2Results posted
- Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)CompletedNCT00775411Phase 2Results posted
- An Extension to Study MD7108240CompletedNCT00733304Phase 2Results posted
- Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)CompletedNCT00729846Phase 2Results posted
- To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMDCompletedNCT00612456Phase 2Results posted
- Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin TrialCompletedNCT00593450Phase 3Results posted
- Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)CompletedNCT00511706Phase 2Results posted
- Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)CompletedNCT00492284Phase 2Results posted
- Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular DegenerationCompletedNCT00473642Phase 4Results posted
- Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationCompletedNCT00436553Phase 3Results posted
- Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT00433017Phase 2/3Results posted
- A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular DegenerationTerminatedNCT00395057Phase 2Results posted
- An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVOCompletedNCT00379795Not applicableResults posted
- Ranibizumab in Hemorrhagic Choroidal Neovascularization TrialCompletedNCT00363168Phase 1Results posted
- SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationCompletedNCT00331864Phase 3Results posted
- An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMDTerminatedNCT00327470Phase 4Results posted
- Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular DegenerationCompletedNCT00304954Phase 2Results posted
- Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00284089Phase 1/2Results posted
- A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal PegaptanibCompletedNCT00242580Phase 3Results posted
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour PeriodCompletedNCT07090044Phase 4
- Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous TreatmentCompletedNCT06683950Phase 4
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT06176352Phase 3
- Impact of Non-Exudative Type 1 MNV on AMD ProgressionActive, not recruitingNCT06125977
- NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular DegenerationActive, not recruitingNCT05984927Phase 1/2
- Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVCCompletedNCT05969418
- Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCVCompletedNCT05662943
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Active, not recruitingNCT05536973Phase 2
- Effect of Corona Virus on Intravitreal InjectionsStatus unknownNCT05494775Not applicable
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive, not recruitingNCT05407636Phase 3
- OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.Status unknownNCT05055973
- Brolucizumab for CNV Associated With Pathologic MyopiaStatus unknownNCT04976244Not applicable
- 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)Status unknownNCT04922151Phase 2
- Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved IndicationsCompletedNCT04847895
- Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye DropsCompletedNCT04782271Phase 1
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive, not recruitingNCT04704921Phase 2/3
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Active, not recruitingNCT04645212
- A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)CompletedNCT04524910
- OCTA Metrics Repeatability and Reproducibility in Different DisordersStatus unknownNCT04488887
- Time Efficiency Comparison of Two IntraVitreal Injection TechniquesCompletedNCT04455399Not applicable
- Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central ChorioretinitisStatus unknownNCT04245072Not applicable
- Treatment of Polypoidal Choroidal Vasculopathy in PachychoroidCompletedNCT04075188Not applicable
- Intravitreal Conbercept Injection in Patients With Myopic Choroidal NeovascularizationCompletedNCT03971162Not applicable
- Antiangiogenic Therapy of Choroidal Neovascularisation Associated With MyopiaCompletedNCT03963596Not applicable
- Imaging of the Angiofibrotic Switch in Neovascular AMDStatus unknownNCT03838679
- Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth FactorCompletedNCT03793400
- OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)WithdrawnNCT03435926
- SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to MyopiaCompletedNCT03409250Phase 4
- Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMDCompletedNCT03393767Phase 4
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular DegenerationCompletedNCT03249740Phase 1
- Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral ImagingTerminatedNCT03105609